RAPP Q4 2025 Earnings — Rapport Therapeutics, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

RAPPRapport Therapeutics, Inc. Common Stock

$1B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$39M

Net Income

-$34M

EPS (Diluted)

$-0.72

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$512M

Total Liabilities

$28M

Stockholders' Equity

$485M

Cash & Equivalents

$53M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$39M	-$24M	-63.7%
Net Income	-$34M	-$20M	-69.0%